Neoplasma. 2017;64(3):430-436. doi: 10.4149/neo_2017_314.
This study aims to investigate the predictive values of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in evaluating the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer. Between September 2011 and December 2014, a total of 174 patients with locally advanced breast cancer treated with NAC were selected for this study. Conventional CT and MRI examinations (DWI and DCE-MRI) were performed in all patients before NAC (T0), after the first course (T1) and after the whole course (T2) of NAC. According to the response evaluation criteria in solid tumors (RECIST), patients were divided into the effective [complete response (CR) + partial response (PR)] and ineffective groups [stable disease (SD) + disease progression (DP)]. The Apparent diffusion coefficient (ADC), maximum tumor diameter, the early-phase enhancement rate (Ee), maximal enhanced rate of tumor (E max), maximal linear slope (S max), maximal excretion rate (E wash), signal intensity (SI), maximal signal rise velocity (V max) and area under the curve (AUC) of Cho before and after NAC were calculated. Receiver operating characteristic (ROC) curve was drawn and the AUC of change rate of ADC values and semi-quantitative parameter were utilized to analyze the diagnostic performance of them for evaluating the efficacy of NAC for breast cancer. There were 135 patients in the effective group, with 52 cases of CR and 83 cases of PR; 39 patients were in the ineffective group, with 14 cases of PD and 25 cases of SD. The effective rate of NAC for breast cancer was 77.6%. The ADC values of the two groups significantly increased but the maximum tumor diameter, E e, E max, S max, E wash and AUC of Cho greatly decreased. The effective group had higher ADC values, its change rate and tumor regression rate than the ineffective group. However, the maximum tumor diameter, E e, E max, S max, E wash, AUC of Cho, SI and V max in the effective group were remarkably lower than those in the ineffective group. The change rate of ADC mean achieved the highest evaluation efficiency with AUC of 0.920, sensitivity of 80.0% and specificity of 94.9%. The optimal critical value was 36.49 (× 10-3mm2/s). In conclusion, these results demonstrated that the change rate of ADC mean values and E e could be promising tools for evaluating the efficacy of NAC in patients with breast cancer.
本研究旨在探讨弥散加权成像(DWI)和动态对比增强磁共振成像(DCE-MRI)在评估乳腺癌新辅助化疗(NAC)疗效中的预测价值。2011 年 9 月至 2014 年 12 月,共选择了 174 例接受 NAC 治疗的局部晚期乳腺癌患者进行本研究。所有患者在 NAC 前(T0)、第一个疗程后(T1)和整个疗程后(T2)均行常规 CT 和 MRI 检查(DWI 和 DCE-MRI)。根据实体瘤反应评估标准(RECIST),患者被分为有效组(完全缓解[CR]+部分缓解[PR])和无效组(疾病稳定[SD]+疾病进展[DP])。计算 NAC 前后表观扩散系数(ADC)、最大肿瘤直径、早期增强率(Ee)、肿瘤最大增强率(E max)、最大线性斜率(S max)、最大排泄率(E wash)、信号强度(SI)、最大信号上升速度(V max)和 Cho 曲线下面积(AUC)。绘制受试者工作特征(ROC)曲线,利用 ADC 值变化率和半定量参数的 AUC 分析其对评估乳腺癌 NAC 疗效的诊断性能。有效组 135 例,CR 52 例,PR 83 例;无效组 39 例,PD 14 例,SD 25 例。乳腺癌 NAC 的有效率为 77.6%。两组 ADC 值均显著升高,而最大肿瘤直径、Ee、E max、S max、E wash 和 Cho AUC 均显著降低。有效组的 ADC 值、变化率和肿瘤退缩率均高于无效组,但最大肿瘤直径、Ee、E max、S max、E wash、Cho AUC、SI 和 V max 均显著低于无效组。ADC 均值变化率的 AUC 为 0.920,灵敏度为 80.0%,特异性为 94.9%,评估效率最高。最佳临界值为 36.49(×10-3mm2/s)。综上所述,ADC 均值变化率和 Ee 可作为评估乳腺癌 NAC 疗效的有前途的工具。